SCM
PRAX icon

Soleus Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Soleus Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.4M Sell
177,517
-153,000
-46% -$48.4M 2.05% 12
2026
Q1 		$106M Sell
330,517
-32,449
-9% -$10M 4.31% 7
2025
Q4 		$107M Sell
362,966
-496,200
-58% -$92.4M 3.95% 5
2025
Q3 		$45.5M Sell
859,166
-107,574
-11% -$5.22M 2.29% 16
2025
Q2 		$40.7M Sell
966,740
-173,000
-15% -$6.59M 2.69% 11
2025
Q1 		$43.2M Buy
1,139,740
+896,200
+368% +$56M 3.11% 10
2024
Q4 		$18.7M Sell
243,540
-15,858
-6% -$1.15M 1.18% 26
2024
Q3 		$14.9M Sell
259,398
-273,617
-51% -$14.8M 1.16% 33
2024
Q2 		$22M Buy
533,015
+495,747
+1,330% +$23.4M 1.94% 17
2024
Q1 		$2.27M Buy
+37,268
New +$1.67M 0.17% 75
2023
Q4 		– Sell
-76,667
Closed -$1.97M – 98
2023
Q3 		$1.97M Sell
76,667
-63,333
-45% -$1.2M 0.18% 69
2023
Q2 		$2.42M Buy
+140,000
New +$2.14M 0.27% 69

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Soleus Capital Management's PRAX Position: Q2 2026 in Review

Soleus Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 46% in Q2 2026, selling an estimated $48.4M and leaving 177,517 shares worth $59.4M. The position accounts for 2.05% of the portfolio, ranked #12.

Soleus Capital Management first reported a position in PRAX in Q2 2023 and has held it in 12 quarters since. The position peaked at $107M in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Soleus Capital Management held 177,517 shares of Praxis Precision Medicines worth $59.4M as of Q2 2026.
  • Soleus Capital Management sold 153,000 Praxis Precision Medicines shares in Q2 2026, an estimated $48.4M.
  • Praxis Precision Medicines made up 2.05% of Soleus Capital Management's portfolio in Q2 2026, its #12 holding.
  • Soleus Capital Management first reported a position in Praxis Precision Medicines in Q2 2023 and has held it in 12 quarters since.
  • Soleus Capital Management's Praxis Precision Medicines position peaked at $107M in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.